Multiple Sclerosis - Demonstration Project
Multiple Sclerosis (MS) phenotype algorithm for the DNA Databank demonstration project.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
ICD 9 Codes
Non-alcoholic fatty liver disease (NALFD) & Alcoholic Fatty Liver Disease (ALD)
Non-alcoholic fatty liver disease (NAFLD)
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Opioid-exposed infants
Objective
Observational studies examining outcomes among opioid-exposed infants are limited by phenotype algorithms that may under identify opioid-exposed infants without neonatal opioid withdrawal syndrome (NOWS). We developed and validated the performance of different phenotype algorithms to identify opioid-exposed infants using electronic health record (EHR) data.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Ovarian/Uterine Cancer (OvUtCa)
The KPWA/UW-led ovarian/uterine cancer phenotype has been validated at Mayo Clinic, the secondary phenotype development site. Validation results at both the primary and secondary sites were strong and the phenotype is ready for network wide implementation. The pseudo code document posted 11/30/2017 is correct as is and should be used by network sites for phenotype implementation. A validated data dictionary of covariates for this phenotype will be added to PheKB by 2/15/2018, but sites are encouraged to begin implementing the phenotype algorithm now.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Peripheral Arterial Disease - 2012
Peripheral Arterial Disease (PAD) is prevalent with approximately 10-12 million adults in US affected. For those with PAD, morbidity and mortality are high and quality of life is markedly impaired. The genetic basis of PAD is poorly understood and is the focus of the Mayo Clinic Electronic Medical Records and Genomics (eMERGE) Network study.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
PGx medication risk prediction model
This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences. This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.
For more information on PREDICT, see http://mydruggenome.org.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
PhEMA BPH (Benign Prostatic Hyperplasia) cases
This is PhEMA (Phenotype Execution Modeling Architecture, projectphema.org)'s implementation of the following BPH (Benign Prostatic Hyperplasia) case algorithm from the following BPH case and control algorithm on PheKB:
https://phekb.org/phenotype/benign-prostatic-hyperplasia-bph
Artifacts for this phenotype, inc. an HQMF representation, a KNIME workflow that can run against an i2b2 instance, and a snapshot of the PhAT graphical representation, are posted on GitHub:
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Pneumonia- VUMC eMERGE v5.1
Identify bacterial pneumonia, similar to that reported with genetic association risk in CD143 and TLR4 A229G in literature.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Post-event Pain algorithm
Pain is a personal, multidimensional experience in which genetic biomarkers has a main role in determining pain sensitivity, perception and tolerance. Pain is a major concern for surgical patients and post-operative pain management still present a major challenge both in inpatient or outpatient settings. Apart from genetic factors, there are many other variables that may affect pain perception for example, pretreated patients may require less post-surgical medications, and they may recover more quickly.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Red Blood Cell Indices
Laboratory results for ESR and RBC indices (hemoglobin, MCV, MCH, RDW… etc) should be extracted from the Laboratory databases. For Mayo, from January 1994 till October 2009, ESR and RBC test results were populated for our 3336 participants. All samples were collected on an outpatient basis. Samples collected during an inpatient hospitalization (admit date ≤ collection date ≤ discharge date) should be excluded unless this sample was the only one available for a patient.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final